Market Overview - The A-share market experienced an overall increase on May 29, with the Shanghai Composite Index closing at 3363.45 points, up 0.7%, the Shenzhen Component Index at 10127.2 points, up 1.24%, and the ChiNext Index at 2012.55 points, up 1.37%. The North Star 50 Index rose by 2.73%. Total trading volume reached 12136.01 billion yuan, an increase of 1795.28 billion yuan compared to the previous trading day [1]. Capital Flow - The net inflow of main funds in the A-share market was 74.33 billion yuan, with an opening net outflow of 19.58 billion yuan and a closing net inflow of 23.89 billion yuan [2]. - The net inflow for the CSI 300 was 12.91 billion yuan, while the ChiNext saw a net inflow of 42.65 billion yuan, and the STAR Market experienced a net outflow of 17.3 billion yuan [4]. Sector Performance - Among the 23 sectors, the computer industry led with a net inflow of 191.73 billion yuan, followed by the electronics sector with 124.39 billion yuan, and the pharmaceutical and biological sector with 112.04 billion yuan. The non-bank financial sector saw a net inflow of 47.51 billion yuan, while the communication sector had 34.87 billion yuan [6][7]. - The sectors with the largest net outflows included food and beverage with -21.56 billion yuan, basic chemicals with -12.02 billion yuan, and banking with -8.89 billion yuan [7]. Individual Stock Activity - The stock with the highest net inflow was Shanzhi Gaoke, with 7.11 billion yuan [8]. - Institutional investors showed significant interest in several stocks, with Wangzi New Materials receiving a net buy of 41.11 million yuan, and Sifang Precision receiving 36.17 million yuan [11][12]. Institutional Focus - Recent institutional ratings highlighted several stocks, including Huichuan Technology with a target price of 73.00 yuan, indicating an upside potential of 8.83%, and Longying Precision with a target price of 24.70 yuan, suggesting a 19.73% upside [14].

Investment Rating - The report assigns a "Buy-A" investment rating for the company, with a target price of 15.00 CNY for the next six months [5]. Core Insights - The company is transitioning into an international innovative pharmaceutical enterprise, with its innovative pipeline gradually entering a harvest period [10]. - The company has made significant progress in its large molecule innovative drugs, particularly with the product Yilishu, which has received approval for sale in 34 countries [30][54]. - The small molecule drug segment focuses on differentiation through a strategy of "small, sharp, and special," with a stable growth in sales [59]. - The traditional Chinese medicine segment has a wide range of products, including several exclusive varieties, contributing to steady growth [62]. Summary by Sections 1. Company Overview - The company focuses on research and innovation in the pharmaceutical health sector, with a diverse product pipeline in various therapeutic areas [10]. - The controlling shareholder holds 42.85% of the company's shares, indicating strong ownership [13]. 2. Large Molecule Innovative Drugs - The company has made advancements in its research pipeline, with Yilishu being a key product that has received approvals in multiple countries [30]. - The domestic market strategy includes a commercial partnership with Zhengda Tianqing to enhance sales [51]. - The global market for G-CSF drugs is expected to grow, with the company positioned to benefit from this trend [52]. 3. Small Molecule Drugs - The company has established a differentiated product layout in the small molecule drug sector, focusing on key products that have shown stable sales growth [59]. 4. Traditional Chinese Medicine - The company has a broad layout in traditional Chinese medicine, with several exclusive products contributing to its revenue growth [62]. 5. Raw Material Business - The company maintains a leading position in the vitamin B5 market, with stable demand expected to drive growth [67]. 6. Profit Forecast and Valuation Analysis - The company is projected to achieve revenues of 60.42 billion CNY, 70.30 billion CNY, and 81.29 billion CNY from 2025 to 2027, with corresponding net profits of 6.09 billion CNY, 7.40 billion CNY, and 8.88 billion CNY [74].

Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 2.39% as of May 29, 2025, with notable gains in constituent stocks such as Zhaoyan New Drug (603127) up 9.99%, Yifan Pharmaceutical (002019) up 9.17%, and Dizhe Pharmaceutical (688192) up 8.73% [1] - The Biovaccine ETF (159657) rose by 2.28%, with the latest price reported at 0.63 yuan [2] - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3, 2025, in Chicago, showcasing the development of oncology research in China, with over 70 studies from Chinese scholars selected for presentation [2] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) as of April 30, 2025, include Fosun Pharma (600196), Changchun High-tech (000661), and others, collectively accounting for 63.18% of the index [3] - The Biovaccine ETF closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry, reflecting the overall performance of quality listed companies in the sector [2]

Core Viewpoint - The company Yifan Pharmaceutical has successfully completed the first shipment of its innovative drug F-627 to the U.S. market, marking a significant milestone in its international expansion [1] Group 1: Product Launch - F-627, also known as Ryzneuta, is the world's first third-generation long-acting G-CSF drug for increasing white blood cell counts [1] - The drug has received approval for sale in multiple regions, including China, the U.S., the EU, and Brazil [1] Group 2: Market Expectations - Based on current order conditions, the company anticipates shipping approximately 40,000 units overseas by 2025 [1] - The drug has been successfully included in China's medical insurance directory following negotiations in 2023 [1]

Core Viewpoint - The announcement details the pledge and release of shares by Cheng Xianfeng, the controlling shareholder of Yifan Pharmaceutical Co., Ltd, indicating changes in shareholding structure and potential implications for the company's stock performance [2][4]. Share Pledge Details - Cheng Xianfeng pledged 5.24% of his shares, amounting to 2.14% of the company's total share capital, starting from May 25, 2025 [2]. - The pledge was made to China Galaxy Securities Co., Ltd [2]. Share Release Details - Cheng Xianfeng released 22,000,000 shares, which represents 4.43% of his total holdings and 1.81% of the company's total share capital, effective from May 27, 2025 [2]. - The shares were also released from pledge to China Galaxy Securities Co., Ltd [2]. Cumulative Pledge Situation - As of the announcement date, Cheng Xianfeng and his concerted actors have a total of pledged shares, with the cumulative pledged amount being significant [2]. - The report indicates the proportion of pledged shares relative to total holdings and the company's total share capital [2][4].

证券代码：002019 证券简称：亿帆医药 公告编号：2025-036 亿帆医药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、股东股份累计被质押的情况 截至本公告披露日，程先锋先生及其一致行动人所持股份质押情况如下： | 股东名称 | 持股数 量 | 持股比 | 累计质押 数量 | 占其所 持股份 | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占公司总 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | 例 | | | 股本比例 | 限售和冻结 | 押股份 | 限售和冻结 | 押股份 | | | （股） | | （股） | 比例 | | | | | | | | | | | | | 数量（股） | 比例 | 数量（股） | 比例 | | 程先锋 | 496,526, | 40.82 | 69,500,00 | 14.00% | ...

Group 1 - The company has approved a cash dividend distribution plan for the year 2024, proposing to distribute 1 RMB per 10 shares to all shareholders, totaling approximately 121.64 million RMB [1][2] - The distribution will be based on the company's total share capital of 1,216,390,085 shares, excluding repurchased shares, with adjustments made if the total share capital changes before the distribution [1][2] - The dividend tax rates will vary for different types of shareholders, with specific provisions for Hong Kong investors and domestic investors holding different classes of shares [1][2] Group 2 - The record date for the dividend distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [2] - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies or other custodial institutions [2] - The company assumes all legal responsibilities and consequences for any insufficient cash dividends distributed [2]

035 证券代码：002019 证券简称：亿帆医药 公告编号：2025- 4、本次实施分派方案距股东会审议通过的时间未超过两个月。 二、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本剔除已回购股份0股 后的1,216,390,085股为基数，向全体股东每10股派1.000000元人民币现金（含税； 扣税后，通过深股通持有股份的香港市场投资者（特别说明：请上市公司根据自 身是否属于深股通标的证券，确定权益分派实施公告保留或删除该类投资者）、 境外机构（含QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每10 股派0.900000元；持有首发后限售股、股权激励限售股及无限售流通股的个人股 息红利税实行差别化税率征收，本公司暂不扣缴个人所得税，待个人转让股票时， 根据其持股期限计算应纳税额【注】；持有首发后限售股、股权激励限售股及无 亿帆医药股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）2024年年度权益分派方案已获 2025年5月20日召开的2 ...

法律意见书 根据《中华人民共和国公司法》（下称《公司法》）、《中华人民共和国证 券法》（下称《证券法》）、中国证券监督管理委员会（下称"中国证监会"） 《上市公司股东会规则》（下称《股东会规则》）以及《亿帆医药股份有限公司 公司章程》（下称《公司章程》）等有关规定，安徽天禾律师事务所接受亿帆医 药股份有限公司（下称"亿帆医药"或"公司"）委托，指派王炜、罗明伟律师 （下称"天禾律师"）出席公司 2024 年年度股东会（下称"本次股东会"）， 对本次股东会相关事项进行见证，并出具法律意见。 本法律意见书是天禾律师根据对有关本次股东会事实的了解及对我国现行 法律、法规和规范性文件的理解而做出的。 天禾律师同意将本法律意见书作为本次股东会的必备文件予以公告并依法 对所出具的法律意见书承担责任。 天禾律师根据有关法律、法规的要求，按照律师行业公认的业务标准、道德 规范和勤勉尽责的精神，对本次股东会的召集和召开程序、出席会议人员的资格、 表决程序及其他相关法律问题发表法律意见如下： 一、本次股东会的召集与召开程序 （一）2025 年 4 月 24 日，公司召开第八届董事会第十六次会议，通过了《关 于召开 2024 年年 ...

亿帆医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东会无否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-034 （一）会议召开情况 一、会议召开和出席情况 1、会议召开的日期、时间 现场会议召开的时间：2025 年 5 月 20 日下午 1:30 起 网络投票的时间：2025 年 5 月 20 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 20 日上午 9:15 至 9:25，9:30 至 11:30，下午 13:00 至 15:00； 通过深圳证券交易所互联网投票系统进行网络投票，开始时间为 2025 年 5 月 20 日上午 9:15 至下午 15:00。 2、现场会议召开地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口， 合肥亿帆生物制药有限公司会议室 3、召集人：公司董事会 4、会议方式：本次会议采取现场投票和网络投票相结合的方式 5、会议主持人：董事长程先锋 ...